• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥密克戎变异株 SARS-CoV-2 在上海:13120 例老年患者的临床特征和灭活疫苗疗效。

Omicron variant of SARS-COV-2 in Shanghai: Clinical features and inactivated vaccine efficacy in 13,120 elderly patients.

机构信息

Department of Gastroenterology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China.

Department of Radiology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China.

出版信息

Int J Med Sci. 2023 Jul 24;20(9):1144-1151. doi: 10.7150/ijms.84452. eCollection 2023.

DOI:10.7150/ijms.84452
PMID:37575277
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10416717/
Abstract

Few reports concerning inactivated vaccine efficacy in elderly patients with Omicron infection. We aimed at demonstrating the clinical characteristics of elderly patients with mild disease and assessing the protective effect of the vaccine preliminarily. 13,120 mild patients who aged beyond 60 years old were included in this study totally, medical records were collected and analyzed. Patients beyond 60 years had more chronic comorbidities, significantly lower ORF1ab and N gene CT values, and longer time of nucleic acid conversion than other age groups. Higher CT value of ORF1ab and N gene were found in older patients who received a booster dose of vaccine than in those who received two doses. The time of nucleic acid conversion was longest in unvaccinated old patients, with a decreasing trend from those who received two doses to those who received a booster doses. We also used random forest and logistic regression to screen for factors strongly associated with nucleic acid conversion and to predict the time of nucleic acid conversion. For mild patients with Omicron infection, patients aged>60 years had mild clinical symptoms, higher viral loads, and longer time of nucleic acid conversion, when compared with younger patients. The inactivated SARS-CoV-2 vaccine provided effective protection among adults with omicron variant infection, and the effectiveness of three doses of the vaccine was greater than that of two doses of the vaccine. Special attention should be given to elderly patients.

摘要

关于奥密克戎感染老年患者灭活疫苗效力的报告较少。我们旨在展示轻症老年患者的临床特征,并初步评估疫苗的保护作用。本研究共纳入 13120 例 60 岁以上的轻症患者,收集并分析其病历。60 岁以上患者合并慢性基础疾病更多,ORF1ab 和 N 基因 CT 值显著更低,核酸转阴时间更长。与接种两剂疫苗的患者相比,接种加强针疫苗的老年患者 ORF1ab 和 N 基因 CT 值更高。未接种疫苗的老年患者核酸转阴时间最长,从接种两剂疫苗到接种加强针疫苗呈逐渐下降趋势。我们还使用随机森林和逻辑回归筛选与核酸转换时间密切相关的因素,并预测核酸转换时间。对于奥密克戎感染的轻症患者,与年轻患者相比,>60 岁的老年患者临床症状较轻,病毒载量更高,核酸转阴时间更长。灭活 SARS-CoV-2 疫苗为奥密克戎变异株感染的成年人提供了有效保护,三剂疫苗的有效性大于两剂疫苗。应特别关注老年患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a99/10416717/e9ae8e222bd8/ijmsv20p1144g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a99/10416717/ae55d880d861/ijmsv20p1144g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a99/10416717/e9ae8e222bd8/ijmsv20p1144g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a99/10416717/ae55d880d861/ijmsv20p1144g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a99/10416717/e9ae8e222bd8/ijmsv20p1144g002.jpg

相似文献

1
Omicron variant of SARS-COV-2 in Shanghai: Clinical features and inactivated vaccine efficacy in 13,120 elderly patients.奥密克戎变异株 SARS-CoV-2 在上海:13120 例老年患者的临床特征和灭活疫苗疗效。
Int J Med Sci. 2023 Jul 24;20(9):1144-1151. doi: 10.7150/ijms.84452. eCollection 2023.
2
[Characteristics and related factors of viral nucleic acid negative conversion in children infected with Omicron variant strain of SARS-CoV-2].[新型冠状病毒奥密克戎变异株感染儿童病毒核酸转阴的特征及相关因素]
Zhonghua Er Ke Za Zhi. 2022 Dec 2;60(12):1307-1311. doi: 10.3760/cma.j.cn112140-20220623-00582.
3
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
4
Transmission Characteristics and Inactivated Vaccine Effectiveness Against Transmission of SARS-CoV-2 Omicron BA.5 Variants in Urumqi, China.中国乌鲁木齐市 SARS-CoV-2 奥密克戎 BA.5 变异株传播特征和灭活疫苗对传播的有效性。
JAMA Netw Open. 2023 Mar 1;6(3):e235755. doi: 10.1001/jamanetworkopen.2023.5755.
5
Circulating eosinophils associated with responsiveness to COVID-19 vaccine and the disease severity in patients with SARS-CoV-2 omicron variant infection.循环嗜酸性粒细胞与 COVID-19 疫苗反应性和 SARS-CoV-2 奥密克戎变异感染患者疾病严重程度相关。
BMC Pulm Med. 2023 May 22;23(1):177. doi: 10.1186/s12890-023-02473-w.
6
Vaccination status for mild and asymptomatic infections with SARS-CoV-2 Omicron BA.2 variant in Shanghai.上海市 SARS-CoV-2 奥密克戎 BA.2 变异株轻症和无症状感染者的疫苗接种情况。
J Med Virol. 2023 May;95(5):e28767. doi: 10.1002/jmv.28767.
7
Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.BNT162b2 和 CoronaVac 新冠疫苗对奥密克戎 BA.2 亚谱系引起的 SARS-CoV-2 无症状和有症状感染的有效性:一项前瞻性队列研究。
Lancet Infect Dis. 2023 Apr;23(4):421-434. doi: 10.1016/S1473-3099(22)00732-0. Epub 2022 Dec 12.
8
[Analysis of clinical characteristics of patients with different vaccines and underlying diseases infected with novel coronavirus Omicron variant].[不同疫苗接种情况及合并基础疾病的新型冠状病毒奥密克戎变异株感染患者临床特征分析]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022 Jun;34(6):571-575. doi: 10.3760/cma.j.cn121430-20220415-00378.
9
Impact of inactivated vaccines on decrease of viral RNA levels in individuals with the SARS-CoV-2 Omicron (BA.2) variant: A retrospective cohort study in Shanghai, China.灭活疫苗对奥密克戎(BA.2 )变异株个体中病毒 RNA 水平下降的影响:中国上海的一项回顾性队列研究。
Front Public Health. 2023 Mar 7;11:1107343. doi: 10.3389/fpubh.2023.1107343. eCollection 2023.
10
Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death.新冠病毒奥密克戎 BA.2 变异株感染、重症和死亡的灭活疫苗和 Ad5-nCoV 新冠疫苗有效性。
BMC Med. 2022 Oct 20;20(1):400. doi: 10.1186/s12916-022-02606-8.

引用本文的文献

1
Effect of COVID-19 vaccine in adults infected with the Delta variant of SARS-CoV-2: a retrospective cohort study.新冠病毒 2019 年病疫苗对感染严重急性呼吸综合征冠状病毒 2 型德尔塔变异株的成年人的影响:一项回顾性队列研究。
J Thorac Dis. 2024 Oct 31;16(10):6983-6998. doi: 10.21037/jtd-24-1351. Epub 2024 Oct 15.
2
A Retrospective Study on COVID-19 Infections Caused by Omicron Variant with Clinical, Epidemiological, and Viral Load Evaluations in Breakthrough Infections.奥密克戎变异株突破性感染的临床、流行病学和病毒载量评估的 COVID-19 感染回顾性研究。
Int J Med Sci. 2024 Jan 1;21(3):454-463. doi: 10.7150/ijms.87167. eCollection 2024.

本文引用的文献

1
Mortality Risk Among Patients Hospitalized Primarily for COVID-19 During the Omicron and Delta Variant Pandemic Periods - United States, April 2020-June 2022.在奥密克戎和德尔塔变异株流行期间因 COVID-19 住院的患者的死亡率风险 - 美国,2020 年 4 月-2022 年 6 月。
MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1182-1189. doi: 10.15585/mmwr.mm7137a4.
2
Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January-March 2022.2022 年 1 月至 3 月,香港 SARS-CoV-2 奥密克戎 BA.2 变异株感染的流行病学。
Emerg Infect Dis. 2022 Sep;28(9):1856-1858. doi: 10.3201/eid2809.220613. Epub 2022 Aug 1.
3
The Association between Risk Perception and Hesitancy toward the Booster Dose of COVID-19 Vaccine among People Aged 60 Years and Older in China.
中国60岁及以上人群对新冠病毒疫苗加强针的风险认知与犹豫态度之间的关联
Vaccines (Basel). 2022 Jul 12;10(7):1112. doi: 10.3390/vaccines10071112.
4
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.比较分析英国住院和死亡风险与 SARS-CoV-2 奥密克戎(B.1.1.529)和德尔塔(B.1.617.2)变异株的关系:一项队列研究。
Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16.
5
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study.美国奥密克戎、德尔塔和阿尔法 SARS-CoV-2 变异株的 mRNA 疫苗对新冠病毒的临床严重程度和有效性:前瞻性观察研究。
BMJ. 2022 Mar 9;376:e069761. doi: 10.1136/bmj-2021-069761.
6
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎(B.1.1.529)变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
7
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.疫苗预防严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)感染和 COVID-19 疾病有效性的持续时间:系统评价和荟萃回归的结果。
Lancet. 2022 Mar 5;399(10328):924-944. doi: 10.1016/S0140-6736(22)00152-0. Epub 2022 Feb 23.
8
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
9
Omicron variant and booster COVID-19 vaccines.奥密克戎变种与新冠病毒加强疫苗
Lancet Respir Med. 2022 Feb;10(2):e17. doi: 10.1016/S2213-2600(21)00559-2. Epub 2021 Dec 17.
10
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review.比较 COVID-19 疫苗在针对 SARS-CoV-2 及其关注变异株的特性、疗效和有效性方面的差异:一项叙述性综述。
Clin Microbiol Infect. 2022 Feb;28(2):202-221. doi: 10.1016/j.cmi.2021.10.005. Epub 2021 Oct 27.